🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Prostatic Neoplasm

Access to Genetic Testing in Underserved Patients With Cancer NCT06422455NA2 sites📍 Los Angeles📍 Rochester University of Southern California · Tests: Best Practice, Educational Intervention, Electronic Health Record Review, Genetic Counseling, Interview Utrecht Prostate Cohort for Cancer Treatment Intervention Studies and Long-term Evaluation NCT04228211n/a2 sites📍 Nieuwegein📍 Utrecht UMC Utrecht A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan NCT06099093Phase 42 sites📍 Boston📍 Boston Brigham and Women's Hospital · Tests: 18F-DCFPyl 99mTc-P137 SPECT/CT in Prostate Cancer NCT05672485NA1 site📍 Xi'an First Affiliated Hospital Xi'an Jiaotong University · Tests: SPECT/CT imaging with 99mTc-P137 nuclide probe Prostate SABR With Intra-Prostatic SABR Boost NCT04212715Phase 21 site📍 Riyadh King Saud University · Tests: Pelvic SABR with intra-prostatic SABR Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer NCT07216248Phase 21 site📍 Salt Lake City University of Utah · Tests: relugolix + ARPI, Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI, relugolix or androgen deprivati… This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned. NCT05946824Phase 21 site📍 Rochester University of Rochester · Tests: Daily-adaptive Stereotactic Body Radiation Therapy, Daily-adaptive Stereotactic Body Radiation Therapy Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer NCT03678025Phase 3338 sites📍 Gilbert📍 Phoenix📍 Phoenix SWOG Cancer Research Network · Tests: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide The COSMYC Trial (COmbined Suppression of MYC) NCT06922318Phase 21 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue 24 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer NCT05936736NA1 site📍 Milan IRCCS San Raffaele · Tests: prostate SBRT T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer NCT05586360Phase 22 sites📍 Atlanta📍 Charleston Medical University of South Carolina · Tests: Simvastatin 40mg A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer NCT06609005Phase 1, Phase 222 sites📍 Scottsdale📍 Newport Beach📍 Orange Shenzhen Ionova Life Sciences Co., Ltd. · Tests: INV-9956 Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole SRT Versus SRT+ADT in Prostate Cancer NCT05019846Phase 31 site📍 Brescia Marco Lorenzo Bonu · Tests: Triptorelin Embonate, Bicalutamide 50 mg SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization NCT06389097n/a1 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Radium-223, 177Lu-DOTATATE, 177Lu-PSMA-617 A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors NCT05932862Phase 116 sites📍 Fountain Valley📍 Jacksonville📍 Orlando Exelixis · Tests: XL309, Olaparib Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Efficacy Testing NCT06785441n/a1 site📍 Houston M.D. Anderson Cancer Center 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer NCT07145177Phase 11 site📍 San Francisco University of California, San Francisco · Tests: 177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE), Positron Emission Tomography (PET)/Computerized tomo… Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE) NCT06705803n/a2 sites📍 Hyde Park📍 Cincinnati University of Chicago · Tests: Prostate Ablation Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery NCT02706561NA1 site📍 New York Memorial Sloan Kettering Cancer Center · Tests: questionnaires, three in-person sessions, monthly phone calls, Acceptance and Commitment Therapy for Erectile Dysfuncti… Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R) NCT07210086Phase 21 site📍 Duarte City of Hope Medical Center · Tests: ADT, ARSI, No ADT/ARSI -decline A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650Phase 3330 sites📍 Tucson📍 Irvine📍 Los Angeles Merck Sharp & Dohme LLC · Tests: Opevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer NCT04986423Phase 231 sites📍 Los Angeles📍 San Francisco📍 Whittier Zenith Epigenetics · Tests: ZEN003694, Enzalutamide Delayed Pelvic Imaging With [68]Ga-PSMA PET/CT in a Patient With High-risk Prostate Cancer. NCT07357259NA1 site📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna · Tests: Intervention Group Virtual Biopsy of Prostate Cancer Using PSMA PET and AI NCT07266129n/a1 site📍 Tromsø University Hospital of North Norway Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer NCT05753566Phase 22 sites📍 Nanjing📍 Nanjing The Affiliated Nanjing Drum Tower Hospital of Nanjing Unive… · Tests: Rezvilutamide, Androgen deprivation therapy (ADT), SRT Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial NCT06720532n/a1 site📍 Munich Hannah Schaefer · Tests: characterization of renal function., Handgrip strength test, Questionaires Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy NCT07711314Phase 21 site📍 Nanjing The Affiliated Nanjing Drum Tower Hospital of Nanjing Unive… · Tests: Rezvilutamide Tablets Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma NCT06567314Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Ivonescimab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy